The Lancet Neurology in conversation with
by The Lancet Group
Is this your podcast?Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 4 chart positions in 4 markets.
By chart position
- 🇲🇽MX · Medicine#4230K to 100K
- 🇮🇪IE · Medicine#159500 to 3K
- 🇨🇱CL · Medicine#187500 to 3K
- 🇵🇱PL · Medicine#188500 to 3K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
16K to 55K🎙 Weekly cadence·67 episodes·Last published 1mo ago - Monthly Reach
Unique listeners across all episodes (30 days)
32K to 109K🇲🇽92%🇮🇪3%🇨🇱3%+1 more - Active Followers
Loyal subscribers who consistently listen
9.4K to 33K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 10 epsHosts
Recent guests
Recent episodes
Jan D Lünemann and Christian Münz on Epstein–Barr virus and multiple sclerosis
Jul 15, 2026
15m 45s
Hal Dietz discusses the role of genetics in spinal CSF leaks
Jun 17, 2026
16m 23s
Tony Schapira on GBA1 Parkinson's disease
Jun 16, 2026
26m 05s
Henry Brodaty and Alice Powell on cognitive resilience and ageing
Apr 17, 2026
23m 11s
Niklas Mattsson-Carlgren on the use of biomarkers in the diagnosis and stratification of Alzheimer’s disease
Mar 18, 2026
16m 06s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 7/15/26 | Epstein-Barr virusmultiple sclerosis+3 | Jan LünemannChristian Münz | University of British ColumbiaUniversity of Zürich+3 | — | Epstein-Barr virusmultiple sclerosis+3 | — | 15m 45s | ||
| 6/17/26 | geneticsspinal CSF leaks+5 | Hal Dietz | Johns Hopkins MedicineThe Lancet Neurology+2 | Baltimore, USA | geneticsspinal CSF leaks+7 | — | 16m 23s | ||
| 6/16/26 | GBA1 Parkinson's diseasegenetic links+3 | Tony Schapira | GBA1UCL’s Queen Square Institute of Neurology+1 | — | GBA1Parkinson's disease+5 | — | 26m 05s | ||
| 4/17/26 | cognitive resilienceageing+4 | Henry BrodatyAlice Powell | University of New South WalesThe Lancet Neurology | — | cognitive reservebrain maintenance+5 | — | 23m 11s | ||
| 3/18/26 | biomarkersAlzheimer's disease+3 | Niklas Mattsson-Carlgren | p-tau217eMTBR-tau243+2 | — | biomarkersAlzheimer's disease+3 | — | 16m 06s | ||
| 2/18/26 | migraine preventionCGRP pathway+3 | Cristina Tassorelli | University of PaviaThe Lancet | — | migraineCGRP+5 | — | 24m 01s | ||
| 1/21/26 | prion diseasesgenetic factors+4 | Inga ZerrSimon Mead | DZNEUCL London+1 | — | prion diseasesgenetic factors+4 | — | 30m 11s | ||
| 12/19/25 | Parkinson's diseaseclinical trials+3 | Dr Julia Greenland | azathioprineThe Lancet+1 | — | Parkinson's diseaseazathioprine+3 | — | 15m 06s | ||
| 11/12/25 | dementiaLewy bodies+4 | Ian McKeith | Newcastle University | — | dementiaLewy bodies+5 | — | 16m 54s | ||
| 10/15/25 | stroke riskwomen's health+4 | Ask Nordestgaard | Brigham and Women's HospitalThe Lancet | Boston | strokewomen+5 | — | 11m 48s |
Showing 10 of 10
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart history for The Lancet Neurology in conversation with
Peaked at #42 in Mexico, currently #42 in Mexico.
| Market | Genre | Peak | Current | Trend |
|---|---|---|---|---|
| Mexico | — | #42 | #42 | — |
| Ireland | — | #159 | #159 | — |
| CL | — | #187 | #187 | — |
| PL | — | #188 | #188 | — |
Chart Positions
4 placements across 4 markets.
Chart Positions
4 placements across 4 markets.